Litcius/Paper detail

Human papillomavirus E5 suppresses immunity via inhibition of the immunoproteasome and STING pathway

Sayuri Miyauchi, Sangwoo S. Kim, Riley N. Jones, Lin Zhang, Kripa Guram, Sonia Sharma, Stephen P. Schoenberger, Ezra E.W. Cohen, Joseph A. Califano, Andrew B. Sharabi

2023Cell Reports52 citationsDOIOpen Access PDF

Abstract

The role that human papillomavirus (HPV) oncogenes play in suppressing responses to immunotherapy in cancer deserves further investigation. In particular, the effects of HPV E5 remain poorly understood relative to E6 and E7. Here, we demonstrate that HPV E5 is a negative regulator of anti-viral interferon (IFN) response pathways, antigen processing, and antigen presentation. Using head and neck cancer as a model, we identify that E5 decreases expression and function of the immunoproteasome and that the immunoproteasome, but not the constitutive proteasome, is associated with improved overall survival in patients. Moreover, immunopeptidome analysis reveals that HPV E5 restricts the repertoire of antigens presented on the cell surface, likely contributing to immune escape. Mechanistically, we discover a direct interaction between E5 and stimulator of interferon genes (STING), which suppresses downstream IFN signaling. Taken together, these findings identify a powerful molecular mechanism by which HPV E5 limits immune detection and mediates resistance to immunotherapy.

Topics & Concepts

StingImmune systemImmunotherapyInterferonAntigenImmunologyBiologyAntigen presentationCancer immunotherapyHPV infectionStimulator of interferon genesCancer researchInnate immune systemCancerT cellGeneticsCervical cancerAerospace engineeringEngineeringinterferon and immune responsesUbiquitin and proteasome pathwaysvaccines and immunoinformatics approaches